Newsletter

Stay up to date on all things atrial fibrillation. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Share this post on your profile with a comment of your own:

Successfully Shared!

View on my Profile

Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation

January 24, 2020

Overview

The goal of this study is to see how electrogram morphology recurrence (EMR) mapping works on patients with atrial fibrillation, in order to pinpoint areas of high EMR rate. The study will help determine if this technology is able to terminate or slow atrial fibrillation. The investigator will use EMR mapping on the patients’ atrial fibrillation to indicate locations of stable activity and ablate the area.

 

Study Information

10 subjects will be enrolled in the study. The primary purpose of the trial is treatment. The study began on April 4, 2017 and is estimated to be completed by December 31, 2020.

 

Inclusion Criteria

 

  • Men and women of at least 21 years of age
  • Persistent atrial fibrillation (AF) with one prior failed ablation for persistent or long standing persistent AF.

 

Exclusion Criteria

 

  • Inability to sign consent
  • Patients with a life expectancy less than one year
  • Patients with chronic kidney disease with sufficiently low GFR that precludes either CT angiogram of the heart or contrast MRI study
  • Pregnant women and women that are breastfeeding
  • Patients with multiple (2 or more) prior failed ablations
  • Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.

 

Location

The study will take place at the University of Miami, Miami, Florida, United States, 33136. If you have any questions, please contact Raul Mitrani, MD at 305-243-5070 / rmitrani@med.miami.edu.

 

Sponsors / Collaborators

The study is sponsored by Jeffery Goldberger of the National Heart, Lung, and Blood Institute (NHLBI). The principal investigator is Raul Mitrani, MD of the University of Miami.

View All Clinical Trials

Clinical Trials

Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation

This study aims to survey patients with atrial fibrillation in order to understand direct-acting oral anticoagulant (DOAC) treatment from the…

iCLAS for Persistent Atrial Fibrillation

This study aims to evaluate the safety of the Adagio AF Cryoablation System (iCLAS™) for ablation treatment of persistent atrial fibrillation.…

Esophageal Deviation in Atrial Fibrillation Ablation

Ablation treatment in the posterior wall of the left atrium can cause thermal injury to the esophagus, which is a very common occurrence. The goal…

Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter

The goal of this study is to compare heart rate control (heart rate <110 beats per minute) at 2 hours after taking the medication diltiazem…

Low Voltage-Directed Catheter Ablation for Atrial Fibrillation

The goal of this study is to determine the long term success of non-paroxysmal ablation to treat atrial fibrillation using three different…

The Genetic Basis for Atrial Fibrillation

Veteran patients with atrial fibrillation will be examined for common genetic polymorphisms, and identify…

Liraglutide Effect in Atrial Fibrillation

The goal of this study is to use a medication called Liraglutide to reduce fat deposits surrounding the heart, and…

High-resolution MRI of Atrial Fibrillation Patients Prior to Focal Impulse and Rotor Modulation (FIRM) Ablation

The goal of the study is to find a correlation between FIRM targeted sites and micro-anatomic fibrotic tracks. Patients will first undergo a…

Send this to a friend